New CAR-T therapy targets lupus and arthritis in early trial
NCT ID NCT07152223
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 30 times
Summary
This study tests a new treatment using a patient's own immune cells, modified to target two proteins (CD19 and BCMA), for connective tissue diseases like lupus and rheumatoid arthritis. The goal is to see if it is safe and can control the disease. About 20 people will take part in this early-stage trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONNECTIVE TISSUE DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dongguan Taixin Hospital
RECRUITINGDongguan, Guangdong, 523125, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.